[Changes in lower urinary tract function in children with hyperactive urinary bladder treated with combined therapy]

Area of Science:

• Pediatric Urology
• Pharmacology
• Urodynamics

Context:

• Conservative therapy for hyperactive bladder (HB) in children often faces challenges due to the low clinical efficacy of anticholinergic medications (M-cholinolytics).
• Optimizing treatment strategies for pediatric lower urinary tract dysfunction is crucial for improving patient quality of life and preventing long-term complications.

Purpose:

• To evaluate the efficacy of a combined therapeutic approach using pikamilon and driptan for treating hyperactive bladder in pediatric patients.
• To investigate the relationship between urodynamic parameters, specifically mean effective bladder capacity, and treatment response in children with HB.

Summary:

• A study involving 57 children (7-14 years) with hyperactive bladder assessed the effectiveness of combined pikamilon and driptan therapy.
• Uroflowmetry and cystometry were used to evaluate treatment outcomes, revealing that the response to therapy correlated with mean effective bladder capacity.
• Urodynamic investigations indicated that improved lower urinary tract function is pathogenetically significant for successful treatment of pediatric urologic conditions associated with HB.

Impact:

• This study suggests that combined therapy with pikamilon and driptan may offer a more effective treatment option for pediatric hyperactive bladder compared to monotherapy.
• Understanding the role of bladder capacity in treatment response can help tailor therapeutic interventions for better outcomes in children with urologic pathology.
• The findings highlight the importance of urodynamic assessment in managing pediatric lower urinary tract dysfunction and optimizing treatment strategies.